Shares of Amicus Therapeutics FOLD moved higher by 0.2% in pre-market trading after the company reported Q4 results.
Earnings per share rose 22.86% over the past year to ($0.27), which missed the estimate of ($0.23).
Revenue of $70,571,000 higher by 27.63% from the same period last year, which beat the estimate of $70,060,000.
Amicus Therapeutics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Mar 01, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/pikiqnf7
52-week high: $25.39
Company's 52-week low was at $6.25
Price action over last quarter: down 39.91%
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Currently, the company is focused on treating Fabry Disease with its treatment Galafold and developing additional therapies for Fabry patients. Amicus has also received breakthrough therapy designation that allows it to deploy a therapy for Pompe Disease in late-stage patients.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.